Medpace (NASDAQ:MEDP) was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Friday, February 16th.
Other research analysts have also issued reports about the company. Robert W. Baird lifted their target price on Medpace from $32.00 to $35.00 and gave the stock a “neutral” rating in a report on Tuesday, October 31st. Zacks Investment Research lowered Medpace from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. Jefferies Group lifted their price target on Medpace from $34.00 to $38.00 and gave the stock a “hold” rating in a research note on Wednesday, November 1st. Finally, William Blair cut Medpace from an “outperform” rating to a “market perform” rating in a research note on Wednesday, November 1st. They noted that the move was a valuation call. Eight research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $36.83.
Medpace (NASDAQ MEDP) traded up $0.37 during trading hours on Friday, reaching $35.95. The company had a trading volume of 188,956 shares, compared to its average volume of 257,618. The firm has a market capitalization of $1,350.00 and a price-to-earnings ratio of 39.51. Medpace has a 1 year low of $21.76 and a 1 year high of $39.64. The company has a current ratio of 0.67, a quick ratio of 0.67 and a debt-to-equity ratio of 0.46.
Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 26th. The company reported $0.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.01. The firm had revenue of $99.45 million for the quarter, compared to analyst estimates of $97.25 million. Medpace had a return on equity of 10.55% and a net margin of 8.97%. Medpace’s revenue was up 4.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.35 earnings per share. equities analysts anticipate that Medpace will post 1.88 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently modified their holdings of MEDP. BlackRock Inc. lifted its holdings in Medpace by 136.0% in the 4th quarter. BlackRock Inc. now owns 1,124,978 shares of the company’s stock worth $40,793,000 after purchasing an additional 648,204 shares during the last quarter. Vanguard Group Inc. increased its position in Medpace by 23.3% in the 2nd quarter. Vanguard Group Inc. now owns 1,014,439 shares of the company’s stock worth $29,419,000 after buying an additional 191,597 shares during the period. Acadian Asset Management LLC increased its position in Medpace by 6.9% in the 4th quarter. Acadian Asset Management LLC now owns 633,743 shares of the company’s stock worth $22,979,000 after buying an additional 40,944 shares during the period. Ameriprise Financial Inc. increased its position in Medpace by 88.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 416,101 shares of the company’s stock worth $13,266,000 after buying an additional 195,284 shares during the period. Finally, Granite Investment Partners LLC increased its position in Medpace by 5.5% in the 3rd quarter. Granite Investment Partners LLC now owns 295,415 shares of the company’s stock worth $9,424,000 after buying an additional 15,486 shares during the period. 23.60% of the stock is currently owned by hedge funds and other institutional investors.
Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.